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Summary
It has been reported that interferon (IFN)-g-secreting T cells reactive to gluten
can be detected in the peripheral blood of individuals with treated coeliac
disease (CD) after a short consumption of wheat-containing food. By con-
trast, very little is known about the reproducibility of this in-vivo procedure in
the same patient cohort which underwent two, or more, gluten consumptions.
Fourteen coeliac patients in remission consumed wheat bread for 3 days; 13
underwent a second gluten challenge after a wash-out of 3–10 months on a
strict gluten-free diet. Immune reactivity to gluten was analysed in peripheral
blood by detecting IFN-g before and 6 days after commencing a gluten diet.
Gliadin-specific IFN-g-secreting CD4+ T cells increased significantly on day 6
of the first challenge. These cells resulted as prevalently human leucocyte
antigen (HLA)-DQ restricted and with a phenotype of gut homing, as sug-
gested by the expression of b7-integrin. Similarly, reactiveness to gliadin was
observed after the second wheat consumption, although with an individual
variability of responses at each challenge. Our findings confirmed that the
short wheat challenge is a non-invasive approach to investigate the gluten-
related immune response in peripheral blood of subjects intolerant to gluten.
Furthermore, we demonstrated that the in-vivo procedure can be reproduced
in the same subject cohort after a gluten wash-out of at least 3 months. Our
study has important implications for the application of this procedure to
clinical practice.
Keywords: ELISPOT, in-vivo challenge, interferon-g, peripheral blood, wheat
gluten
Accepted for publication 11 April 2012
Correspondence: C. Gianfrani, Institute of Food
Sciences-CNR, Via Roma 64, 83100 Avellino,
Italy.
E-mail: cgianfrani@isa.cnr.it
Introduction
Coeliac disease (CD) is a chronic enteropathy due to an
abnormal immune reaction to gluten, the storage proteins of
wheat, barley and rye [1]. Gluten peptides escaping proteoly-
sis from gastrointestinal enzymes activate proinflammatory
T cells that play a central role in the induction of mucosal
atrophy in coeliac patients [1]. Great progress in understand-
ing CD pathogenesis has come from the use of gluten-
specific T cell clones and T cell lines raised from intestinal
biopsies [2,3]. This approach, although very successful in
defining immune reactivity to gluten, required prolonged
in-vitro cell culturing and the use of growth factors, with
the risk of alterations of cell phenotype and function. Ander-
son and co-workers established an innovative approach
that allows the detection of gluten-specific T cells in the
peripheral blood of CD patients after a short period of
gluten-containing food consumption [4,5]. Basically, gluten-
sensitized CD4+ T cells, normally scarcely detectable in the
blood of coeliac patients, circulate transiently in the periph-
eral blood after 3 days of wheat challenge, and can be
detected by a sensitive interferon (IFN)-g enzyme-linked
inmmunospot (ELISPOT) assay. Using this in-vivo proce-
dure, the authors further screened large libraries of prolamin
peptides and assessed the hierarchy and immunodominance
of gluten T cell epitopes [6]. More recently, T cells reactive to
DQ2-a-I and DQ2-a-II epitopes were monitored in the
peripheral blood of bread-challenged coeliacs with specific
DQ2-tetramer constructs [7,8]. Of note, both Australian and
Norwegian studies enrolled adult coeliac volunteers, with an
average age of 43 years. To our knowledge, no information is
available on the responsiveness to short gluten challenge in
very young coeliac patients. Furthermore, very little is
known about the in-vivo challenge reproducibility in the
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same subject cohort, with the exception of a few cases of
coeliacs who underwent two separate gluten consumptions
described in the above-mentioned studies [7,8].
In the present study we have validated the in-vivo short
gluten challenge in a cohort of 14 young CD patients of
Italian origin. In particular, we analysed the peripheral blood
response against whole gliadin and the immunodominant
33-mer peptide (a-gliadin 57–89). We also assessed the fea-
sibility of exposing the patient cohort to a second in-vivo
challenge after a period of 3–10 months of wash-out, in
order to estimate the reproducibility of the procedure in the
same study population and the intra-individual variations.
If replicated successfully in other studies, the short wheat
challenge could represent a strategic tool to evaluate non-
invasively the individual’s response to gluten, and could be
applied to intervention studies. In fact, the evaluation of
small bowel mucosa damage after long-term wheat challenge
has been used since the 1950s to assess cereal toxicity or to
define the toxic peptides [9–11]. Such studies required
repeated endoscopies, before and after treatment, which are
always not well accepted by participants. To detect a dysregu-
lated response to gluten, other functional markers, such as
faecal fat and xylose malabsorption, resulted in low specific-
ity and sensitivity [12–15]. Furthermore, recent studies have
indicated that a short gluten challenge could be used to
support diagnosis in doubtful cases of CD [16–18].
Patients and methods
Patients and in-vivo wheat challenge procedure
Fourteen DQ2-positive volunteers with CD (mean age 18·6,
range 15–24 years) participated in the study (Table 1). All
patients received the diagnosis of CD during their paediatric
age (mean age 4·7, range 1–12 years), according to the Euro-
pean Society of Paediatric Gastroenterology and Nutrition
(ESPGHAN) criteria [19], and were followed-up regularly at
the Department of Pediatrics, University Federico II, Naples.
Patients were informed about the aim of the study and gave
their full consent. The study was approved by the Ethical
Committee of Department of Pediatrics, University Federico
II, Naples. The serum level of endomysium (EMA) and tissue
transglutaminase (anti-tTG) antibodies [immunoglogbulin
(Ig)A] was measured immediately before both gluten chal-
lenges started (day 0). EMA were detected by indirect immu-
nofluorescence on frozen sections of human umbilical cord
and anti-tTG using the enzyme-linked immunosorbent
assay (ELISA) technique with a commercial kit (Eu tTg IgA;
Eurospital, Trieste, Italy). Results were interpreted according
to the manufacturer’s instructions: negative <9 U/ml, weak
positive in the range 9–16 U/ml, positive >16 U/ml. Patients
ate 200 g of wheat bread or cookies daily for 3 days, corre-
sponding to about 12 g of gluten per day (first challenge).
After a wash-out of 3–10 months on a strict gluten-free diet,
13 of 14 coeliacs consumed wheat for an additional 3 days
(second challenge). At the time of the first gluten challenge,
11 patients were seronegative for EMA or anti-tTG and three
had low antibody titres. Two patients complained about
abdominal pain on the first day of the challenge, but they did
not stop the gluten intake. The remaining patients reported
no symptoms.
Antigen preparation
A commercial wheat flour was used for baking the bread and
cookies. Gliadin was extracted according to Wieser et al. [20]
and digested enzymatically with pepsin and trypsin, as
described previously [21]. The 33-mer (a-gliadin 57–89)
Table 1. Patients enrolled into the study.
Patient Age/sex
Duration of
GFD years
1st challenge 2nd challenge Elapsed time (months)
between 1st and 2nd challengeEMA† Anti-tTG‡ EMA† Anti-tTG
Pt 1 21/F 20 Neg 2·8 Neg 2·8 6
Pt 2 15/F 6 Low Pos 30·2 Low Pos 9·2 6
Pt 3 15/F 13 Neg 4·8 Neg 3·8 3
Pt 4 18/M 6 Neg 3·2 Neg 4·2 3
Pt 5 16/F 5 Neg 2 Neg 2·4 3
Pt 6 17/M 16 Neg 0·8 Neg 0·4 10
Pt 7 18/M 17 Neg 2 Neg 2 6
Pt 8 19/F 17 Neg n.d. n.d. n.d. n.d.
Pt 9 17/F 16 Neg 0·4 Neg 1·2 10
Pt 10 20/M 14 Neg 1·8 Neg 2·6 3
Pt 11 19/F 18 Low Pos 38 Low Pos 26 6
Pt 12 22/F 20 Low Pos 5·4 Low Pos 7·6 3
Pt 13 24/F 14 Neg 4 Neg 3·6 6
Pt 14 20/F 13 Neg 0·8 Neg 2 3
†The serum endomysium (EMA) titres were evaluated before the wheat consumption (day 0) of both 1st and 2nd challenge. ‡Anti-tissue trans-
glutaminase (anti-tTG) immunoglobulin (Ig)A sensitivity: negative <9 U/ml, weakly positive in the range 9–16 U/ml, positive >16 U/ml.
GFD, gluten-free diet; pos, positive; neg, negative; F, female; M, male; n.d., not done.
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peptide was synthesized by solid-phase automated flow, as
described elsewhere [2]. Both PT-gliadin (indicated hereaf-
ter as gliadin) and peptides were deamidated with guinea pig
tTG, as reported elsewhere [2].
Detection of IFN-g-secreting cells
Venous blood (15–20 ml) was collected in a heparizined
syringe before (day 0) and 6 days after (day 6) the gluten
challenge. Peripheral blood mononuclear cells (PBMCs)
were isolated by Ficoll-Paque density centrifugation. PBMCs
were analysed immediately for antigen recognition by IFN-g
ELISPOT assay, as described previously [22]. Briefly, 4 ¥ 105
PBMCs were seeded in 200 ml of complete medium
X-Vivo15 supplemented with 5% heat-inactivated AB
pooled human serum, 1% antibiotics (100 U/ml penicillin
and 100 mg/ml streptomycin) and 1% L-glutamine (2 mM)
(all provided by BioWhittaker, Verviers, Belgium) in dupli-
cate in 96-well plates (Millipore, Bedford, MA, USA) coated
with purified anti-human IFN-g antibody (MabTech, Nacka
Strand, Sweden). Gliadin, either deamidated or native, was
tested at 50 mg/ml and 33-mer peptide at 30 mg/ml (7·7 mM).
Cells were incubated for 36–40 h with biotinylated anti-
human IFN-g antibody (MabTech) followed by incubation
with streptavidin horseradish peroxidase (HRP) (BD-
Pharmingen, San Diego, CA, USA). Spot-forming cells (SFC)
were counted by an immunospot analyser (A.EL.VIS, Han-
nover, Germany).
In the experiments with blocking monoclonal antibodies
(mAbs), PBMCs were incubated with anti-DQ (10 mg/ml,
clone SPV-L3; Biodesign International, Saco, ME, USA) at
37°C for 15 min,before the addition of deamidated gliadin. In
depletion experiments of b7-integrin or CD4-positive cells,
PBMCs were first incubated with phycoerythrin (PE)-
conjugated b7-integrin or CD4 mAbs, and thereafter sepa-
rated using anti-PE-conjugated magnetic beads (Miltenyi
Biotec, Bergisch Gladbach, Germany), according to the
manufacturer’s instructions. In the functional experiments,
total PBMCs, CD4-negative and b7-integrin-negative frac-
tions were plated at 4 ¥ 105 cells/well, while both b7-integrin-
positive and CD4-positive cells were plated at 1 ¥ 105 cells/
well in the presence of 1 ¥ 105 DQ2-positive Epstein–Barr
virus B cells (EBV) as antigen-presenting cells (APC).
Statistical analysis and responsiveness criteria
All experiments were performed in duplicate. All variables at
days 0 and 6 did not show normal distribution, estimated by
skewness and kurtosis; hence, a non-parametric paired-
sample Wilcoxon rank-sum test was used to compare day 6
versus day 0. Data (mean standard deviation of duplicates,
or median and interquartile range 25–75) are expressed as
total IFN-g-SFC/4 ¥ 105 PBMCs, or as net IFN-g-SFC/
4 ¥ 105 (SFC detected in the presence of gliadin/peptides
subtracted the SFC detected with medium alone), as
indicated. Intra-assay variability was determined by stimu-
lating with medium alone, or with deamidated gliadin, over
six replicates of PBMCs from two separate individuals on
day 6 of the first challenge. The intra-assay variation coeffi-
cient of IFN-g-SFC/4 ¥ 105 cells was 15·4%. Patients were
considered responsive to oral gluten challenge when they
showed an increase in SFC in response to gliadin and/or
33-mer peptide by three times the value observed before the
gluten challenge started (fold increase 3), and a difference
(DSFC) of at least 10 SFC/well between days 6 and 0.
Results
Peripheral blood response upon the first short
wheat challenge
Fourteen DQ2-positive patients, aged between 15 and 24
years, participated in the study (Table 1). Two patients
reported significant clinical symptoms during, and soon
after, the 3 days’ consumption of bread. Of note, these two
symptomatic patients had low EMA/anti-tTG titres at the
time the challenge began.
Peripheral blood mononuclear cells were tested for reac-
tivity to either deamidated gliadin or 33-mer peptide (cor-
responding to the immunodominant a-gliadin 57–89) by
detecting the IFN-g-secreting cells at days 0 and 6 of the
wheat challenge. In response to gliadin stimulation, the IFN-
g-SFC increased significantly in peripheral blood at day 6:
median and interquartile range (25–75th centiles) of net
IFN-g-SFC/4 ¥ 105 cells were 15·3 (7·0–39·5) and 66·5 (31·3–
162·2) at days 0 and 6, respectively (P = 0·004) (Fig. 1a).
Similarly, the in-vivo gluten challenge induced a significant
increase of IFN-g-positive cells in response to 33-mer: 0·3
(0·01–2·2) and 42·9 (0·5–127·1), respectively, at days 0 and 6
(P = 0·01) (Fig. 1b).
When we evaluated the responsiveness of each individual
coeliac volunteer, according to an arbitrary criterion of
responsiveness (see Methods for details), we observed that 10
of 14 (71%) patients responded to the bread challenge with
an increased IFN-g-SFC to gliadin and/or to 33-mer at day 6
(Table 2).
As mentioned previously, some patients showed weak
EMA/anti-tTG positivity (patients 2, 11 and 12, Table 1). Of
note, two of these three patients responded to the challenge
(Table 2), suggesting that the presence of CD-associated
antibodies, at least at low titres, does not hamper responsive-
ness to the short oral wheat challenge.
Gliadin specificity and intestinal origin of
IFN-g-releasing cells in peripheral blood after the short
wheat challenge
We investigated whether the IFN-g responses elicited in
peripheral blood by short wheat consumption were triggered
Short gluten challenge reproducibility
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specifically by gliadin and, more importantly, if they were
mediated by mucosal activated T cells. Because it is well
documented that the deamidation of gliadin peptides by tTG
strongly increase the stimulation of CD4+ T cells in CD
patients due to the stronger binding of negatively charged
peptides to DQ2/DQ8 HLA molecules [2,3], we evaluated
IFN-g production against either native or deamidated
gliadin in the ELISPOT assay, in order to assess antigen
specificity. As shown in Fig. 2a, IFN-g found at day 6 was
elicited mainly by deamidated gliadin, as the native gliadin
preparation induced approximately 20% of the response
obtained with deamidated gliadin. In addition, the number
of specific spots were reduced strongly upon blocking
HLA-DQ molecules (Fig. 2b), and were abolished almost
completely when we depleted the CD4-positive cells from
the total PBMCs (Fig. 2c). Conversely, the enriched CD4-
positive fractions, with a purity of 99% and 98·66% in
patients 13 and 14, respectively, showed an increased IFN-g
response to gliadin in both patients.
Finally, a crucial question raised when investigating
peripheral blood immune responses against dietary anti-
gens is whether the circulating T cells are primed or
recalled in the gut upon the antigen oral exposure. We
addressed the intestinal origin of the observed response to
gliadin by separating the cell fraction expressing the
b7-integrin, a marker of gut-homing/commitment, from
the PBMCs. Similarly to CD4-positive cells, depletion of
the b7-integrin-expressing cells resulted in a drastic reduc-
tion of the IFN-g-SFC in response to gliadin (75 and 66%
inhibition compared to the response of total PBMCs)
(Fig. 2d), while the b7-integrin-enriched cell fractions, with
a purity of 91·56 and 95·15% in patients 8 and 9, respec-
tively, showed an increased number of spots compared to
those observed in whole PBMCs.
Consistency of peripheral blood response to gliadin in
patients challenged twice
Next we investigated the consistency of the response to gluten
challenge in our cohort of coeliac volunteers who underwent
two separate wheat consumptions performed with the same
procedure. After a wash-out of 3–10 months on a strict
gluten-free diet, 13 of 14 subjects consumed wheat for 3 days
(Table 1). Similarly to the first challenge, a statistically signifi-
cant increase of IFN-g-SFC in response to gliadin was
observed after the second challenge: median and interquartile
range (25–75th centiles) of net IFN-g-SFC/4 ¥ 105 cells were:
37·6 (1·6–150·9) and 152·3 (24·1–292·8) in response to
gliadin, respectively, at days 0 and 6 (P < 0·04) (Fig. 3a); and
0·01 (0·01–6·7) and 4·3 (0·01–17·3) in response to 33-mer,
respectively, at days 0 and 6 (P < 0·04) (Fig. 3b).
Surprisingly, although these donors repeated the wheat
challenge at least 3 months after the first one, and were on a
strict gluten-free diet regimen, the IFN-g-SFC elicited by
gliadin at day 0 of the second challenge was increased if
compared to the SFC obtained just before the first challenge
(median 15·0, interquartile range 7·8–35), although the
increase did not reach statistic significance (P < 0·078). Simi-
larly, the responses observed at day 6 of the second challenge
exceeded those elicited during the first challenge (median
61·0, interquartile range 25·6–166·0), although the difference
was not statistically significant (P = 0·23). Conversely, the
increment of reactivity to the 33-mer peptide was reduced
after the second challenge when compared to the first chal-
lenge (median 22·0, interquartile range 0·33–139·67,
P = 0·1).
When we evaluated individual reactiveness after the
second challenge, seven of 13 (53%) subjects were responsive
to gliadin and/or 33-mer (Table 2). Interestingly, these seven
patients also had a positive response to the first challenge
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Fig. 1. Gliadin-specific interferon (IFN)-g production is elicited in
peripheral blood upon a short (3 days) oral wheat challenge.
Peripheral blood mononuclear cells from young coeliac patients
(n = 14) were analysed for IFN-g enzyme-linked immunospot
(ELISPOT) assay before (day 0) and after (day 6) 3 days of wheat
consumption. IFN-g spot-forming cells (SFC) were assessed in
response to in-vitro stimulation with (a) deamidated gliadin
(50 mg/ml) and (b) deamidated 33-mer peptide (a-gliadin 57–89)
(30 mg/ml/7·7 mM). Dashes indicate the median values of net
IFN-g-responses among patients. *P = 0·01; **P = 0·004 by
non-parametric Wilcoxon’s rank sum test.
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Table 2. Immune response to gliadin and 33-mer after the in-vivo wheat challenges.
1st challenge 2nd challenge
Gliadin 33-mer Gliadin 33-mer
DSFC† FI‡ DSFC† FI‡ DSFC† FI‡ DSFC† FI‡
Pt 1 25 25 0 1 233 234 0 1
Pt 2 368 11·5 81 81 69 1·4 164 5·1
Pt 3 29 1,9 17 17 10 10 0 1
Pt 4 0 0·14 0 0 56 1·3 0 0·7
Pt 5 58 8·2 139 139 81 5,3 0 1
Pt 6 56 56 148 148 0 0·9 11 12
Pt 7 83 1·8 221 2,9 24 1·2 104 2·5
Pt 8 130 15·4 77 77 n.d. n.d n.d. n.d.
Pt 9 225 16 0 0 0 1 14 14
Pt 10 32 2·4 8 8 328 1·6 0 3
Pt 11 16 2·6 22 22 343 8·6 7 7
Pt 12 0 1 0 0 47 1·5 4 4
Pt 13 131 10 79 79 0 0·4 0 0·8
Pt 14 88 2·1 167 167 1 1·1 2 2
†DSFC (spot-forming cells): net interferon (IFN)-g SFC detected on day 6 minus net IFN-g SFC detected on day 0. ‡FI (fold increase): net IFN-g SFC
in response to gliadin/peptide 33-mer observed on day 6 divided by the net IFN-g SFC observed on day 0; n.d., not done.
Fig. 2. Interferon (IFN)-g responses raised
in peripheral blood after the brief wheat
challenge are gliadin-specific and mediated by
DQ-restricted, CD4+ T cells of intestinal origin.
IFN-g enzyme-linked immunospot (ELISPOT)
responses were assessed in peripheral blood
mononuclear cells (PBMCs) of coeliac disease
(CD) subjects on day 6 of the first wheat
challenge in the presence of native or
deamidated gliadin (a). IFN-g ELISPOT
response to deamidated (tTG) gliadin were
assessed in PBMCs in the presence or absence
of anti-DQ antibodies (10 mg/ml) (b). IFN-g
responses were monitored in whole PBMCs
or in CD4– (c) and b7-integrin-depleted cells
(d). Mean values of duplicate wells ( standard
deviation) are reported. One of three
independent experiments is shown in each
panel.
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(Table 2). Conversely, patients 4, 7, 10 and 12 responded to
neither the first nor the second challenges, while the remain-
ing two patients (patients 13 and 14), who responded to
neither gliadin nor 33-mer after the second challenge, had a
substantial increase of IFN-g-secreting cells at the first
challenge. Next, we investigated whether the time elapsed
between the two challenges might have influenced the indi-
vidual responsiveness, but no correlation was observed with
the increment of response to gliadin and to 33-mer (Pear-
son’s correlation: r = -0·264, P > 0·3 and r = 0·312, P > 0·2,
respectively). Overall, our findings indicated a concordance
of responsiveness to the short wheat challenges (considered
either as positive or negative responses) in 11 of 13 (85%) of
the patients, and confirm that short gluten consumption is a
valid and reproducible tool to monitor immune reactiveness
to gluten.
Discussion
The detection in peripheral blood of gluten-reactive T cells
that have been activated, or primed, in the gut-associated
lymphoid tissue during gluten consumption might have
important therapeutic and diagnostic implications in CD. In
this context, the short-term oral wheat challenge, reported
first by Anderson and co-workers, is a simple and safe
method that allows analysis and quantification of gluten-
reactive T cells raised in peripheral blood of coeliac patients
after 3 days of wheat consumption [4–6]. In view of a poten-
tial translational practice of the short-term wheat challenge,
it is crucial to replicate the in-vivo procedure in different
patient cohorts, as well as to assess its reproducibility in the
same individual. To our knowledge, this test was replicated
by another research group in a Norwegian cohort of adult
CD patients [7,8]. In the present study we validated this
method in a cohort of 14 young CD patients recruited in the
south of Italy, and estimated the level of its reproducibility by
exposing the same individual twice to gluten consumption.
After the first in-vivo challenge we observed a significant
increase of IFN-g-secreting cells in response to gliadin 6 days
after the wheat intake, confirming the data reported in both
Australian and Norwegian adult coeliac patients [4,7,8,23].
Similarly, the magnitude of the IFN-g responses was compa-
rable to the values found in previous studies [4–7]. When we
looked at individual responses we found that, upon wheat
consumption, the frequency of IFN-g-releasing cells to
whole gliadin increased at least three times in eight of 14
(57%) subjects, barely within the average obtained in previ-
ous studies, that ranged from 40% [23] to 90% [5] of
exposed coeliac patients. In agreement with these studies, the
specific response to gluten elicited by the in-vivo challenge
was mediated by CD4+ T cells and was DQ2-restricted. Fur-
thermore, the IFN-g-producing cells expressed beta-7 inte-
grin, indicating a phenotype of gut-homing cells.
Short-term gluten consumption also induced a significant
increase of T cells reacting to the immunodominant 33-mer
peptide, although contrasting findings were reported on
the frequency of responder patients [2,3]. Anderson and
co-workers reported that the great majority of coeliacs
reacted to 33-mer (or to truncated peptide, a-gliadin (57–
73) [5,6], while in a more recent study reactivity was
observed in only six of 10 patients [23]. Our results are in
agreement with this latter finding, as we found an evident
increase of IFN-g responses induced by immunodominant
gliadin peptide in 8 of 14 patients at first challenge. Unex-
pectedly, upon the second challenge the number of reacting
subjects was far fewer (three of 13 subjects challenged). In
this regard, we found that approximately 50% of intestinal T
cell lines generated from south Italian CD patients who were
assayed in vitro reacted to 33-mer, suggesting that only a
subgroup of our coeliac donors seems to display a response
to this epitope [2]. These data are not surprising because,
despite its strong immunogenicity, 33-mer is one of several
∗
∗
0
0
5
10
15
20
240
200
160
120
80
40
Day 0 Day 6
Days from challenge
Day 0 Day 6
Days from challenge
100
200
300
400
(a)
(b)
N
et
 IF
N
-γ
-S
F
C
/4
×
10
5  
P
B
M
C
s
N
et
 IF
N
-γ
-S
F
C
/4
×
10
5  
P
B
M
C
s
500
600
700
800
900
Fig. 3. Consistency of interferon (IFN)-g responses in coeliac patients
underwent two separate wheat challenges. Responsiveness to gliadin in
13 coeliac patients underwent a second short wheat consumption
after 3–10 months of a strict gluten-free diet (wash-out). Peripheral
blood mononuclear cells (PBMCs) were assayed by enzyme-linked
immunospot (ELISPOT) for recognition of deamidated gliadin (a) or
33-mer (b) on day 0 and day 6 of oral challenge. Results are shown as
in Fig. 1. Dashes indicate the median values of IFN-g responses
among patients (*P < 0·04).
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gliadin-derived T cell epitopes active in coeliac patients
[2,6], and this could explain the increased magnitude of
IFN-g-positive cells found in response to whole gliadin
digest. In contrast to previous studies, in which the immune
reactivity to gluten was very low, or totally absent, before
wheat consumption at day 0, we also found substantial IFN-g
production instead. It cannot be excluded that in some CD
patients, gliadin-reactive T cells circulate in the peripheral
blood as resting memory cells, and their detection does not
require in-vivo gluten stimulation. Corroborating this
hypothesis, a marked proliferation triggered by gliadin was
reported in the peripheral blood of treated CD patients in
the absence of gluten oral load, and accounted for predomi-
nantly by memory CD4+ T cells [24–26]. In addition, CD8+ T
lymphocytes reactive to a gliadin peptide and restricted by
the HLA class I A2 molecule can be detected by the sensitive
IFN-g-ELISPOT assay in the peripheral blood of both
treated and untreated CD patients who did not undergo an
in-vivo wheat gluten challenge [22]. Although our coeliac
volunteers declared strict adherence to a gluten-free diet, we
cannot exclude that for some of them an accidental gluten
introduction might have occurred. It can be envisaged that
occasional exposure to gluten could, in some cases, produce
an increased frequency of gluten-reactive T cells detectable
in the blood, associated presumably with the production of
anti-tTG antibodies. However, although we found slight
EMA/anti-tTG-positive titres in three patients, they showed
no evident differences in their response to gluten challenge
compared to the EMA-negative subjects.
In this study we compared the peripheral responses of 13
volunteers who underwent two separate wheat consump-
tions, separated by 3–10 months of a strict gluten-free diet.
We found that the IFN-g responses increased significantly in
peripheral blood sampled 6 days after the second challenge
and, unexpectedly, cells reactive to whole gliadin were often
more frequent than those observed in the first challenge, due
most probably to the increased frequency of memory T cells
activated upon the first gluten exposure. However, the rela-
tively small size of the patient cohort did not allow us to
observe a statistically significant difference in the frequency
of responsive cells at day 0 between the first and second
challenges. Furthermore, there was no significant correlation
between the specific PBMC responses to gluten and the time
elapsed between the two wheat challenges. Overall, our find-
ings suggest that a wash-out of at least 3 months is sufficient
time to raise gluten-specific cells in the blood. Further
studies are required to assess the memory phenotype and life
turnover of circulating T cells raised during the gluten
in-vivo exposure. To our knowledge, reproducibility of the
short gluten challenge in the same study cohort has been
poorly investigated. Importantly, we observed consistent
responsiveness to the two short wheat challenges, either in
terms of positive or negative responses, in 11 of 13 (85%) the
patients. Raki et al. [7] reported a reduction of DQ2-a-I
tetramer-positive T cells in the only patient subjected to a
repeated challenge, suggesting recruitment of specific T cells
in the gut after the first activation. Anderson et al. also
observed an overall reduction of responses to the 17-mer
peptide after the second challenge in seven subjects who were
challenged twice at 3–12 months [5].
Unfortunately, it was not possible to recruit non-coeliac
DQ2-positive control individuals who had not been exposed
previously to gluten for 2–3 years, although these would have
been the ideal controls in our study population.
Additional studies involving a larger number of patients
are required to ascertain the specificity and sensitivity of the
in-vivo gluten challenge, in order to assess its potential suit-
ability as a diagnostic tool, as investigated in a recent study
[16]. To this purpose, it would be interesting to monitor the
reactiveness of small children at the early stage of CD, or in
those with ‘potential’ CD, as well as in first-degree relatives
with the highest risk of developing the disease [17].
In conclusion, in the present study we replicated success-
fully the in-vivo gluten challenge approach in a cohort of 14
adolescent Italian CD patients. The short-term wheat chal-
lenge proved to be a reproducible tool to monitor the
immune response to gluten. Assay replication, as well as
reproducibility, represent crucial prerequisites in view of a
potential application of the short-term oral challenge in a
clinical setting. The design of clinical trials aimed to evaluate
novel therapeutic drugs, or the safety of alternative cereals,
could benefit greatly by this non-invasive short-term
procedure.
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